Use of efavirenz or atazanavir/ritonavir is associated with better ...

6 downloads 0 Views 1MB Size Report
Nov 11, 2014 - (HAART) including efavirenz (EFV), compared with boosted protease inhibitors ... confirmed higher rates of virological success after efavirenz.
Accepted Manuscript Use of efavirenz or atazanavir/ritonavir is associated to better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort Maria Concetta Postorino , Mattia Prosperi , Eugenia Quiros-Roldan , Franco Maggiolo , Simona Di Giambenedetto , Annalisa Saracino , Silvia Costarelli , Silvia Lorenzotti , Laura Sighinolfi , Massimo Di Pietro , Carlo Torti PII:

S1198-743X(14)00088-3

DOI:

10.1016/j.cmi.2014.10.022

Reference:

CMI 87

To appear in:

Clinical Microbiology and Infection

Received Date: 2 July 2014 Revised Date:

8 October 2014

Accepted Date: 23 October 2014

Please cite this article as: Postorino MC, Prosperi M, Quiros-Roldan E, Maggiolo F, Di Giambenedetto S, Saracino A, Costarelli S, Lorenzotti S, Sighinolfi L, Di Pietro M, Torti C, the MASTER Study Group, Use of efavirenz or atazanavir/ritonavir is associated to better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort, Clinical Microbiology and Infection (2014), doi: 10.1016/j.cmi.2014.10.022. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

1

Use of efavirenz or atazanavir/ritonavir is associated to better clinical outcomes of HAART

2

compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort

3 Authors:

5

Maria Concetta Postorino1, Mattia Prosperi2, Eugenia Quiros-Roldan3, Franco Maggiolo4, Simona

6

Di Giambenedetto5, Annalisa Saracino6, Silvia Costarelli7, Silvia Lorenzotti8, Laura Sighinolfi9,

7

Massimo Di Pietro10, Carlo Torti1,3 and the MASTER Study Group.

8

Affiliations:

SC

9

RI PT

4

1. Infectious Diseases Unit, “Magna Graecia” University Catanzaro 2. University of Manchester, UK

11

3. Infectious and Tropical Diseases Institute, University of Brescia

12

4. Ospedali Riuniti Bergamo

13

5. Catholic University of Sacred Heart Rome

14

6. Policlinico di Bari

15

7. Ospedale “S. Gerardo” Monza

16

8.

17

9. “S. Anna” Hospital Ferrara

18

10. “S. M. Annunziata” Hospital Florence

TE D

M AN U

10

EP

Istituti Ospitalieri Cremona

Corresponding author: Carlo Torti, Campus Universitario “Salvatore Venuta”, Viale Europa,

20

Catanzaro, Italy, 88100 Tel: +39 0961 3647162 Fax:+39 0961 364 7544 email: [email protected]

21 22

AC C

19

Running title: Short and mid-term predictors of clinical outcomes during HAART

23 24

Key words: Non-nucleoside reverse transcriptase inhibitors, ritonavir boosted protease inhibitors,

25

first-line therapy, virological response, immunological response, AIDS events, deaths, composite

26

outcome.

1

ACCEPTED MANUSCRIPT

Abstract

28 29

Background

30

Randomized trials and observational cohorts reported higher rates of virological suppression after

31

highly active antiretroviral therapy (HAART) including efavirenz (EFV) compared with boosted

32

protease inhibitors (PIs). Correlations with immunological and clinical outcomes are unclear.

33

Methods

34

Patients of the Italian MASTER cohort who started HAART from 2000 to 2010 were selected. Out-

35

standing outcome (composite outcome for success-COS) was introduced. We evaluated predictors

36

of COS (no AIDS plus CD4+ count >500/mm3 plus HIV-RNA